Across TCGA pan-cancer cohorts, SYS1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SYS1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SYS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYS1 expression acts as an unfavorable survival marker.
CESC, UCEC, and CHOL are the cancer types where SYS1 Mutation most reproducibly stratifies survival.